Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Due Diligence who wrote (8698)	1/31/1999 12:01:00 PM
From: Popiye	Read Replies (1) \| Respond to of 8798

LAJD has approval in china.. LA JOLLA, Calif.--(BW HealthWire)--Jan. 14, 1999--La Jolla Diagnostics Inc. (OTC BB:LAJD), announced today that its subsidiary DiagnosTech Inc. has received confirmation that clinical trials on the company's rapid diagnostic TB test have been successfully completed at Beijing Children's Hospital. This proprietary, patent pending rapid diagnostic test for active tuberculosis is a unique breakthrough product for a disease which is a major problem in many countries. The accuracy of this TB test has been confirmed in three separate clinical trials, and it is currently being sold in several countries with approvals pending in numerous others. Presently there is no other test available that can rapidly determine if the disease is an active state. DiagnosTech's Hong Kong based distributor, Winnimax, plans to submit a formal registration application for the product to the Chinese Ministry of Health this coming March. The World Health Organization (WHO) projects that a total of 1 billion TB tests will be performed annually by the year 2000. Approximately 25 percent of active TB cases occur in China. La Jolla Diagnostics is an emerging company engaged in the development and marketing of state-of-the-art diagnostic tests, health care products and nutraceuticals. The health care and nutraceuticals products, including a treatment for migraine headaches, are formulated using a patented technology. CONTACT: La Jolla Diagnostics Inc. 800/454-6790, Fax 619/454-7851 lajd.com lajd96@aol.com